Dunlap N E, Lane V G, Cloud G A, Tilden A B
Department of Medicine, University of Alabama Medical Center, Birmingham 35294.
Cancer. 1990 Oct 1;66(7):1499-504. doi: 10.1002/1097-0142(19901001)66:7<1499::aid-cncr2820660711>3.0.co;2-g.
The authors examined peripheral blood mononuclear cells from 45 patients with bronchogenic carcinoma to determine natural killer (NK) and lymphokine-activated killer (LAK) activity after in vitro incubation with media alone or media plus interferon gamma (IFN, 200 U/ml) and/or interleukin-2 (IL-2, 100 U/ml). Our results show that lymphocytes from patients with bronchogenic carcinoma can acquire LAK activity, but the level of activity acquired was significantly lower compared with lymphocytes from 25 control subjects when IL-2 cultures were supplemented with 10% autologous human serum (AHS) (15.6% +/- 2.1% specific release versus 26.0% +/- 2.9% specific release, P = 0.004). The LAK activity, defined as cytotoxicity of an NK-resistant cell line, of the patients' lymphocytes was augmented when cells were cultured with both IL-2 and IFN compared with IL-2 alone (P = 0.0001, paired t-test). Control subjects were unchanged (P = 0.09). There was no significant difference between groups of patients with different histologic types of tumor or different stages of disease. The NK activity, defined as killing of NK-sensitive K-562 target cells, of the patients' lymphocytes was not significantly different from that of the controls' lymphocytes (42.8% +/- 3.0% specific release versus 49.3% +/- 3.3% specific release, P = 0.16). These studies indicate the feasibility of IL-2 and IFN therapy in patients with bronchogenic carcinoma.
作者检测了45例支气管源性癌患者的外周血单个核细胞，以确定在单独用培养基或培养基加γ干扰素（IFN，200 U/ml）和/或白细胞介素-2（IL-2，100 U/ml）进行体外培养后自然杀伤（NK）和淋巴因子激活的杀伤（LAK）活性。我们的结果显示，支气管源性癌患者的淋巴细胞能够获得LAK活性，但当IL-2培养物补充10%自体人血清（AHS）时，获得的活性水平与25名对照受试者的淋巴细胞相比显著降低（特异性释放分别为15.6%±2.1%和26.0%±2.9%，P = 0.004）。与单独使用IL-2相比，当细胞同时用IL-2和IFN培养时，患者淋巴细胞的LAK活性（定义为对NK抗性细胞系的细胞毒性）增强（P = 0.0001，配对t检验）。对照受试者无变化（P = 0.09）。不同组织学类型肿瘤或不同疾病阶段的患者组之间无显著差异。患者淋巴细胞的NK活性（定义为对NK敏感的K-562靶细胞的杀伤）与对照淋巴细胞的NK活性无显著差异（特异性释放分别为42.8%±3.0%和49.3%±3.3%，P = 0.16）。这些研究表明IL-2和IFN治疗支气管源性癌患者的可行性。
